 CAMBRIDGE, England, BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc NASDAQ:BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist Bicycle TICA, and BT7455, an EphA2CD137 Bicycle TICA, will be presented in five poster presentations at the Society for Immunotherapy of Cancers SITC 37th Ann 